Skip to content
naulon
Not checkedNot checked for notices yet.

Role of biomarkers to identify individuals with silent cardiac disease to help improve primary prevention

Yahia M. Elrakshy, Akram M. Fayed

The Egyptian Heart Journal · 2014

doi:10.1016/j.ehj.2013.12.062 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

The aim of this study was to evaluate power of identification of silent cardiac target organ damage (TOD) in population receiving primary prevention with the use of biomarkers. Background: Primary prevention of cardiovascular events could be improved by identifying patients with silent cardiac TOD (i.e., myocardial ischemia, systolic dysfunction, diastolic dysfunction, left ventricular hypertrophy or left atrial enlargement). Biomarkers used for screening included high sensitive CRP [hs-CRP] high sensitivity cardiac troponin T [hs-cTnT], or B-type natriuretic peptide [BNP]. Methods: The study included 271 asymptomatic individuals already receiving primary prevention therapy, they had their biomarkers evaluated. Identification of silent cardiac TOD was done by transthoracic echocardiography, stress echocardiography, and/or myocardial perfusion imaging. Carotid – femoral pulse wave velocity. Results: Showed that ninety six (35%) patients had evidence of cTOD. Left ventricular hypertrophy evaluated by LV mass index showed the highest prevalence (32.7%), followed by left ventricular diastolic dysfunction (28.9%), left atrial enlargement (19.1%), systolic dysfunction (10.6%), ischemia (7.1%) and the lowest was PWV (2.7%). The discrimination power as evaluated by area under the curve [AUC] for BNP to identify any form of silent cTOD was 0.79 overall and 0.83 in men, while for hs-cTnT it was 0.70 and 0.74 in women. The combined AUC for BNP and hs-cTnT together was 0.81 and 0.82 in men. Week discrimination power existed for of other biomarkers, with AUCs of 0.61 for microalbuminuria, 0.60 for hs-CRP, and 0.58 for eGFR. Conclusions: Asymptomatic patients treated for primary prevention, existing silent cTOD could be identified by BNP screening. The result of hs-cTnT was weaker than that of BNP. Combining BNP plus hs-cTnT together showed best results. Primary prevention could be improved by Prescreening with BNP ± cTnT followed by phenotyping.

Abstract licence: CC BY

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.